Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8F4W

Crystal structure of acetyltransferase Eis from M. tuberculosis in complex with venlafaxine

Summary for 8F4W
Entry DOI10.2210/pdb8f4w/pdb
DescriptorN-acetyltransferase Eis, 1-[(1R)-2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol, DIMETHYL SULFOXIDE, ... (6 entities in total)
Functional Keywordsdrug resistance, inhibitor, acetylation, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceMycobacterium tuberculosis H37Rv
Total number of polymer chains1
Total formula weight47211.55
Authors
Pang, A.H.,Punetha, A.,Garneau-Tsodikova, S.,Tsodikov, O.V. (deposition date: 2022-11-11, release date: 2023-02-01, Last modification date: 2023-10-25)
Primary citationPang, A.H.,Green, K.D.,Punetha, A.,Thamban Chandrika, N.,Howard, K.C.,Garneau-Tsodikova, S.,Tsodikov, O.V.
Discovery and Mechanistic Analysis of Structurally Diverse Inhibitors of Acetyltransferase Eis among FDA-Approved Drugs.
Biochemistry, 62:710-721, 2023
Cited by
PubMed Abstract: Over one and a half million people die of tuberculosis (TB) each year. Multidrug-resistant TB infections are especially dangerous, and new drugs are needed to combat them. The high cost and complexity of drug development make repositioning of drugs that are already in clinical use for other indications a potentially time- and money-saving avenue. In this study, we identified among existing drugs five compounds: azelastine, venlafaxine, chloroquine, mefloquine, and proguanil as inhibitors of acetyltransferase Eis from , a causative agent of TB. Eis upregulation is a cause of clinically relevant resistance of TB to kanamycin, which is inactivated by Eis-catalyzed acetylation. Crystal structures of these drugs as well as chlorhexidine in complexes with Eis showed that these inhibitors were bound in the aminoglycoside binding cavity, consistent with their established modes of inhibition with respect to kanamycin. Among three additionally synthesized compounds, a proguanil analogue, designed based on the crystal structure of the Eis-proguanil complex, was 3-fold more potent than proguanil. The crystal structures of these compounds in complexes with Eis explained their inhibitory potencies. These initial efforts in rational drug repositioning can serve as a starting point in further development of Eis inhibitors.
PubMed: 36657084
DOI: 10.1021/acs.biochem.2c00658
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon